Meeting
2021 Gastrointestinal Cancers Symposium
INNOVA: Interval or neoadjuvant chemotherapy in rectal cancer—A phase II randomized study comparing interval versus neoadjuvant chemotherapy in magnetic resonance imaging-defined high-risk rectal cancer.
Authors
Ramakrishnan Ayloor Seshadri
Cancer Institute (WIA), Chennai, India
Ramakrishnan Ayloor Seshadri , Trivadi S. Ganesan , Manikandan Dhanushkodi , Arunkumar M N , Shirley Sundersingh
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session: Colorectal Cancer
Track
Colorectal Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
CTRI/2015/01/005385, UTN no: U111111650578
Citation
J Clin Oncol 39, 2021 (suppl 3; abstr 91)
DOI
10.1200/JCO.2021.39.3_suppl.91
Abstract #
91
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2018 Gastrointestinal Cancers Symposium
INNOVA: A phase II randomized study comparing INterval versus NeOadjuVAnt chemotherapy in magnetic resonance imaging-defined high risk rectal cancer.
First Author: Ramakrishnan Ayloor Seshadri
Poster
2023 ASCO Gastrointestinal Cancers Symposium
A phase II study of CAPOXIRI as a neoadjuvant chemotherapy in patients with locally advanced rectal cancer (Colorectal Cancer Treatment Group, MSCSGO).
First Author: Yoshinori Kagawa
Poster
2021 Gastrointestinal Cancers Symposium
Short-course radiotherapy and subsequent CAPOX plus camrelizumab followed by delayed surgery for locally advanced rectal cancer: Short-term results of a phase II trial.
First Author: Zhenyu Lin
Poster
2021 Gastrointestinal Cancers Symposium
Neoadjuvant chemotherapy with modified FOLFOXIRI for locally advanced rectal cancer: A single center phase II trial.
First Author: Wen Zhang